Transferrin and HFE genes interact in Alzheimer's disease risk: the Epistasis Project
暂无分享,去创建一个
Yurii S. Aulchenko | M. Arfan Ikram | Mario Cortina-Borja | Rhian Gwilliam | Naomi Hammond | Panos Deloukas | Cornelia M. van Duijn | Onofre Combarros | Kathryn Robson | Abderrahim Oulhaj | Ignacio Mateo | Reinhard Heun | Olivia Belbin | Kevin Morgan | Gordon K. Wilcock | Patrick G. Kehoe | P. Deloukas | R. Gwilliam | C. Duijn | K. Morgan | K. Brown | A. Smith | P. Kehoe | M. Breteler | O. Combarros | I. Mateo | V. Álvarez | M. Ikram | Naomi Hammond | D. Lehmann | D. Warden | E. Coto | H. Kölsch | Y. Aulchenko | A. Oulhaj | G. Wilcock | O. Belbin | A. Arias-Vasquez | R. Heun | M. Cortina-Borja | C. Morris | K. Robson | M. Schuur | Heike Kölsch | Kristelle Brown | Victoria Alvarez | Eliecer Coto | Maaike Schuur | A. David Smith | Alejandro Arias-Vásquez | Monique M. Breteler | Donald J. Lehmann | Donald R. Warden | Michael G. Lehmann | Chris M. Morris | Rachel Barker | R. Barker | A. Arias-Vásquez | Gordon K. Wilcock | Christopher Morris | Alejandro Arias-Vásquez | Reinhard Heun | Naomi Hammond | A. Arias-Vásquez
[1] F. Di Lorenzo,et al. Iron and aluminum in Alzheimer's disease. , 2013, Neuro endocrinology letters.
[2] J. Connor,et al. Expression of the HFE allelic variant H63D in SH-SY5Y cells affects tau phosphorylation at serine residues , 2011, Neurobiology of Aging.
[3] J. Connor,et al. HFE polymorphisms affect cellular glutamate regulation , 2011, Neurobiology of Aging.
[4] J. Connor,et al. Prolyl-peptidyl isomerase, Pin1, phosphorylation is compromised in association with the expression of the HFE polymorphic allele, H63D. , 2010, Biochimica et biophysica acta.
[5] K. Franz,et al. Minding metals: tailoring multifunctional chelating agents for neurodegenerative disease. , 2010, Dalton transactions.
[6] Isidro Ferrer,et al. Mitochondrial ATP‐Synthase in the Entorhinal Cortex Is a Target of Oxidative Stress at Stages I/II of Alzheimer's Disease Pathology , 2010, Brain pathology.
[7] M. Owen,et al. Suggestive synergy between genetic variants in TF and HFE as risk factors for Alzheimer's disease , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[8] Jim Mintz,et al. Prevalent iron metabolism gene variants associated with increased brain ferritin iron in healthy older men. , 2010, Journal of Alzheimer's disease : JAD.
[9] George Perry,et al. Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. , 2010, Journal of Alzheimer's disease : JAD.
[10] Wei Wang,et al. Quantitative MR phase-corrected imaging to investigate increased brain iron deposition of patients with Alzheimer disease. , 2009, Radiology.
[11] D. Jiang,et al. Ternary complexes of iron, amyloid-beta, and nitrilotriacetic acid: binding affinities, redox properties, and relevance to iron-induced oxidative stress in Alzheimer's disease. , 2009, Biochemistry.
[12] Mario Cortina-Borja,et al. Open Access Journal of Neuroinflammation Replication by the Epistasis Project of the Interaction between the Genes for Il-6 and Il-10 in the Risk of Alzheimer's Disease , 2022 .
[13] M. Kivipelto,et al. Midlife Serum Cholesterol and Increased Risk of Alzheimer’s and Vascular Dementia Three Decades Later , 2009, Dementia and Geriatric Cognitive Disorders.
[14] G. Perry,et al. Getting the iron out: phlebotomy for Alzheimer's disease? , 2009, Medical hypotheses.
[15] K. Blennow,et al. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment , 2009, Neurobiology of Aging.
[16] M. Fornage,et al. Genomewide association studies of stroke. , 2009, The New England journal of medicine.
[17] Hua-wei Ling,et al. Correlation of iron in the hippocampus with MMSE in patients with Alzheimer's disease , 2009, Journal of magnetic resonance imaging : JMRI.
[18] A. Hofman,et al. HFE variants, APOE and Alzheimer's disease: Findings from the population-based Rotterdam Study , 2009, Neurobiology of Aging.
[19] M. Muckenthaler,et al. Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. , 2009, Journal of Alzheimer's disease : JAD.
[20] Mario Cortina-Borja,et al. The synergy factor: a statistic to measure interactions in complex diseases , 2009, BMC Research Notes.
[21] D. Blacker,et al. Assessment of Alzheimer’s disease case–control associations using family-based methods , 2009, neurogenetics.
[22] A. Fagan,et al. Alzheimer’s disease risk variants show association with cerebrospinal fluid amyloid beta , 2009, neurogenetics.
[23] Z. Rahimi,et al. Association between enzymatic and non-enzymatic antioxidant defense mechanism with apolipoprotein E genotypes in Alzheimer disease. , 2008, Clinical biochemistry.
[24] D. Sparks,et al. Microglial dystrophy in the aged and Alzheimer's disease brain is associated with ferritin immunoreactivity , 2008, Glia.
[25] K. Nakashima,et al. Sugar Chains of Cerebrospinal Fluid Transferrin as a New Biological Marker of Alzheimer’s Disease , 2008, Dementia and Geriatric Cognitive Disorders.
[26] W. Streit,et al. Microglial degeneration in the aging brain--bad news for neurons? , 2008, Frontiers in bioscience : a journal and virtual library.
[27] S. Mandel,et al. Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[28] R. Maccioni,et al. Mild cognitive impairment and Alzheimer patients display different levels of redox-active CSF iron. , 2008, Journal of Alzheimer's disease : JAD.
[29] Jim Mintz,et al. Brain ferritin iron may influence age- and gender-related risks of neurodegeneration , 2007, Neurobiology of Aging.
[30] J. Keller,et al. Oxidative inactivation of the proteasome in Alzheimer's disease , 2007, Free radical research.
[31] D. Butterfield,et al. The expression of key oxidative stress-handling genes in different brain regions in alzheimer’s disease , 1998, Journal of Molecular Neuroscience.
[32] D. Blacker,et al. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database , 2007, Nature Genetics.
[33] Cecilia Hidalgo,et al. Calcium, iron and neuronal function , 2007, IUBMB life.
[34] M Worwood,et al. Iron genes, iron load and risk of Alzheimer’s disease , 2006, Journal of Medical Genetics.
[35] Daniela Berg,et al. Iron metabolism in Parkinsonian syndromes , 2006, Movement disorders : official journal of the Movement Disorder Society.
[36] W. Markesbery,et al. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease , 2006, Neurobiology of Aging.
[37] D. Dickson,et al. Induction of vascular amyloidosis-β by oxidative stress depends on APOE genotype , 2006, Neurobiology of Aging.
[38] D. Allan Butterfield,et al. Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: Insights into the development of Alzheimer's disease , 2006, Neurobiology of Disease.
[39] W. Markesbery,et al. Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment , 2006, Journal of neurochemistry.
[40] Reeti Tandon,et al. High-field Magnetic Resonance Imaging of Brain Iron in Alzheimer Disease , 2006, Topics in magnetic resonance imaging : TMRI.
[41] D. Dickson,et al. Induction of vascular amyloidosis-beta by oxidative stress depends on APOE genotype. , 2006, Neurobiology of aging.
[42] J. Morrow,et al. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment , 2005, Annals of neurology.
[43] W. Markesbery,et al. Ribosome Dysfunction Is an Early Event in Alzheimer's Disease , 2005, The Journal of Neuroscience.
[44] L. Messori,et al. The C2 variant of human serum transferrin retains the iron binding properties of the native protein. , 2005, Biochimica et biophysica acta.
[45] K. Sleegers,et al. Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease. , 2005, American journal of epidemiology.
[46] F. Panza,et al. The cathepsin D gene exon 2 (C224T) polymorphism and sporadic Alzheimer's disease in European populations. , 2005, The journals of gerontology. Series A, Biological sciences and medical sciences.
[47] Xiongwei Zhu,et al. Ribosomal RNA in Alzheimer Disease Is Oxidized by Bound Redox-active Iron* , 2005, Journal of Biological Chemistry.
[48] F. Schmitt,et al. Evidence of increased oxidative damage in subjects with mild cognitive impairment , 2005, Neurology.
[49] E. Corder,et al. Transferrin neutralization of amyloid β 25-35 cytotoxicity , 2004 .
[50] A. Hofman,et al. Does bilirubin protect against hemochromatosis gene (HFE) related mortality? , 2004, American journal of medical genetics. Part A.
[51] Paige S. Davies,et al. Expression of the Hereditary Hemochromatosis Protein HFE Increases Ferritin Levels by Inhibiting Iron Export in HT29 Cells* , 2004, Journal of Biological Chemistry.
[52] F. Potocnik,et al. 5- and 6-Glycosylation of Transferrin in Patients with Alzheimer's Disease , 2004, Metabolic Brain Disease.
[53] A. Smith,et al. Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer’s disease , 2004, Journal of Medical Genetics.
[54] H. G. van Eijk,et al. Influence of transferrin glycans on receptor binding and iron-donation , 1997, Glycoconjugate Journal.
[55] H. G. Eijk,et al. Transferrin microheterogeneity in rheumatoid arthritis , 1992, Rheumatology International.
[56] E. Corder,et al. Transferrin neutralization of amyloid beta 25-35 cytotoxicity. , 2004, Clinica chimica acta; international journal of clinical chemistry.
[57] H. Cleve,et al. Genetic transferrin types and iron-binding: a comparative study of a European and an African population sample , 2004, Human Genetics.
[58] H. Chertkow,et al. Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma , 2003, Proteomics.
[59] Paige S. Davies,et al. Mechanisms of HFE-induced regulation of iron homeostasis: Insights from the W81A HFE mutation , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[60] E. Yavin,et al. Pro‐apoptotic signaling in neuronal cells following iron and amyloid beta peptide neurotoxicity , 2003, Journal of neurochemistry.
[61] O. Combarros,et al. Interaction of the H63D Mutation in the Hemochromatosis Gene with the Apolipoprotein E Epsilon 4 Allele Modulates Age at Onset of Alzheimer’s Disease , 2003, Dementia and Geriatric Cognitive Disorders.
[62] 廣瀬 渉. Age-associated increases in heme oxygenase-1 and ferritin immunoreactivity in the autopsied brain , 2003 .
[63] Xudong Huang,et al. An Iron-responsive Element Type II in the 5′-Untranslated Region of the Alzheimer's Amyloid Precursor Protein Transcript* , 2002, The Journal of Biological Chemistry.
[64] A. Townsend,et al. The hemochromatosis protein HFE inhibits iron export from macrophages , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[65] M. Pouchard,et al. Gender‐specific phenotypic expression and screening strategies in C282Y‐linked haemochromatosis: a study of 9396 French people , 2002, British journal of haematology.
[66] J. Trojanowski,et al. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. , 2002, Archives of neurology.
[67] D. Small,et al. Wheat germ agglutinin‐binding glycoproteins are decreased in Alzheimer's disease cerebrospinal fluid , 2001, Journal of neurochemistry.
[68] M. Worwood,et al. HFE mutations, iron deficiency and overload in 10 500 blood donors , 2001, British journal of haematology.
[69] A. Nunomura,et al. Oxidative Damage Is the Earliest Event in Alzheimer Disease , 2001, Journal of neuropathology and experimental neurology.
[70] G. Annoni,et al. The hemochromatosis gene affects the age of onset of sporadic Alzheimer’s disease , 2001, Neurobiology of Aging.
[71] J Tuomilehto,et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study , 2001, BMJ.
[72] Ashley I. Bush,et al. Redox-active iron mediates amyloid-β toxicity , 2001 .
[73] M. Smith,et al. Redox-active iron mediates amyloid-beta toxicity. , 2001, Free radical biology & medicine.
[74] M. Colombo,et al. Wild-type HFE protein normalizes transferrin iron accumulation in macrophages from subjects with hereditary hemochromatosis. , 2000, Blood.
[75] S. Tsuji,et al. Apolipoprotein E allele–dependent antioxidant activity in brains with Alzheimer’s disease , 2000, Neurology.
[76] J. Connor,et al. Alterations in the interaction between iron regulatory proteins and their iron responsive element in normal and Alzheimer's diseased brains. , 2000, Cellular and molecular biology.
[77] Y. Christen,et al. Oxidative Insults Are Associated with Apolipoprotein E Genotype in Alzheimer's Disease Brain , 2000, Neurobiology of Disease.
[78] Mark A. Smith,et al. In Situ Oxidative Catalysis by Neurofibrillary Tangles and Senile Plaques in Alzheimer’s Disease , 2000, Journal of neurochemistry.
[79] Jennifer J. Pointon,et al. Geography of HFE C282Y and H63D mutations. , 2000, Genetic testing.
[80] G. Bartzokis,et al. In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. , 2000, Archives of general psychiatry.
[81] Y. Christen,et al. Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. , 1999, Free radical biology & medicine.
[82] W R Markesbery,et al. The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer's disease patients. , 1999, The American journal of pathology.
[83] M. Smith,et al. Is increased redox-active iron in Alzheimer disease a failure of the copper-binding protein ceruloplasmin? , 1999, Free radical biology & medicine.
[84] J. Trojanowski,et al. Increased F2‐isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[85] W. D. Ehmann,et al. Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain. , 1998, Neurotoxicology.
[86] F. Ye,et al. Increasing striatal iron content associated with normal aging , 1998, Movement disorders : official journal of the Movement Disorder Society.
[87] D. M. Penny,et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[88] L. Beckman,et al. Transferrin C2, metal binding and Alzheimer's disease , 1998, Neuroreport.
[89] R. Wolff,et al. The Hemochromatosis Founder Mutation in HLA-H Disrupts β2-Microglobulin Interaction and Cell Surface Expression* , 1997, The Journal of Biological Chemistry.
[90] P. Lewitt,et al. Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders , 1996, Brain Research.
[91] W. D. Ehmann,et al. Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress , 1996, Journal of the Neurological Sciences.
[92] Jonathan D. Smith,et al. Apolipoprotein E allele–specific antioxidant activity and effects on cytotoxicity by oxidative insults and β–amyloid peptides , 1996, Nature Genetics.
[93] B. Lernfelt,et al. 15-year longitudinal study of blood pressure and dementia , 1996, The Lancet.
[94] D. Schubert,et al. The role of iron in beta amyloid toxicity. , 1995, Biochemical and biophysical research communications.
[95] J. Connor,et al. Transferrin and Iron in Normal, Alzheimer's Disease, and Parkinson's Disease Brain Regions , 1995, Journal of neurochemistry.
[96] J. Connor,et al. A Quantitative Analysis of Isoferritins in Select Regions of Aged, Parkinsonian, and Alzheimer's Diseased Brains , 1995, Journal of neurochemistry.
[97] W. Klein,et al. Iron Levels Modulate α‐Secretase Cleavage of Amyloid Precursor Protein , 1995, Journal of neurochemistry.
[98] Jim Mintz,et al. In vivo evaluation of brain iron in Alzheimer's disease and normal subjects using MRI , 1994, Biological Psychiatry.
[99] C. Morris,et al. Non-haem iron histochemistry of the normal and Alzheimer's disease hippocampus. , 1994, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.
[100] J. Taljaard,et al. Increased frequency of the transferrin C2 subtype in Alzheimer's disease. , 1993, Neuroreport.
[101] J. Connor,et al. Ceruloplasmin levels in the human superior temporal gyrus in aging and Alzheimer's disease , 1993, Neuroscience Letters.
[102] P. Mantyh,et al. Aluminum, Iron, and Zinc Ions Promote Aggregation of Physiological Concentrations of β‐Amyloid Peptide , 1993, Journal of neurochemistry.
[103] G. Hallmans,et al. Transferrin types, iron-binding capacity and body iron stores. , 1993, Human heredity.
[104] K. Savage,et al. Expression of glycosylated and nonglycosylated human transferrin in mammalian cells. Characterization of the recombinant proteins with comparison to three commercially available transferrins. , 1993, Biochemistry.
[105] D. Walker,et al. Lactotransferrin immunocytochemistry in Alzheimer and normal human brain. , 1993, The American journal of pathology.
[106] D. Perl,et al. Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's disease: A laser microprobe (LAMMA) study , 1992, Annals of neurology.
[107] J. Connor,et al. Regional distribution of iron and iron‐regulatory proteins in the brain in aging and Alzheimer's disease , 1992, Journal of neuroscience research.
[108] J. Connor,et al. A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains , 1992, Journal of neuroscience research.
[109] S W Atlas,et al. Deep gray matter hypointensity patterns with aging in healthy adults: MR imaging at 1.5 T. , 1991, Radiology.
[110] D. McLachlan,et al. Intramuscular desferrioxamine in patients with Alzheimer's disease , 1991, The Lancet.
[111] K. Jellinger,et al. Brain iron and ferritin in Parkinson's and Alzheimer's diseases , 1990, Journal of neural transmission. Parkinson's disease and dementia section.
[112] C. Wong,et al. Effects of transferrin genetic phenotypes on total iron-binding capacity. , 1986, Acta haematologica.
[113] G. Beckman,et al. Transferrin C2 as an enhancer of cyto- and genotoxic damage. , 1986, Progress in clinical and biological research.
[114] B. Hallgren,et al. THE EFFECT OF AGE ON THE NON‐HAEMIN IRON IN THE HUMAN BRAIN , 1958, Journal of neurochemistry.
[115] L. Goodman. Alzheimer's disease; a clinico-pathologic analysis of twenty-three cases with a theory on pathogenesis. , 1953, The Journal of nervous and mental disease.